WHO prequalifies diagnostic test to support safer administration of P. vivax malaria treatments.

WHO prequalifies diagnostic test to support safer administration of P. vivax malaria treatments 18 January 2025 -the World Health Organization (WHO) prequalified the first diagnostic test for glucose-6phosphate dehydrogenase (G6PD) deficiency which can help to safely deliver WHO-recommended treatments to prevent relapse of Plasmodium vivax (P.vivax) infection.The prequalification of this G6PD diagnostic test marks a significant milestone in facilitating safe and effective P. vivax malaria treatment, reaffirming WHO's dedication to ensuring equitable access to life-saving health solutions globally.Some 500 000 people die each year from malaria, most of them children.The prequalification of this test immediately followed the prequalification, in early December, of two new tafenoquine products for anti-relapse treatment of P. vivax malaria, and these therapeutics were recommended in updated WHO malaria guidelines released a few days earlier, in late November.